It's newsworthy ABBV is running a Phase-3 study in GT2 patients. How many GT2 patients have been treated with the 2-DAA combo? What were the SVR rates? Would this study be enough for GT2 labeling in Japan?
Note: The Japanese 2-DAA regimen of ABT-450/ABT-267 will result in a 50% higher royalty rate for ENTA than the 3-DAA regimen approved in the US and EU that includes ABT-333.